Journal article
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer
Abstract
IMPORTANCE: Non-small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin has significant data supporting its use as an antineoplastic agent.
OBJECTIVE: To compare chemoradiation alone vs chemoradiation and metformin in stage III NSCLC.
Authors
Skinner H; Hu C; Tsakiridis T; Santana-Davila R; Lu B; Erasmus JJ; Doemer AJ; Videtic GMM; Coster J; Yang AX
Journal
JAMA Oncology, Vol. 7, No. 9, pp. 1324–1332
Publisher
American Medical Association (AMA)
Publication Date
September 1, 2021
DOI
10.1001/jamaoncol.2021.2318
ISSN
2374-2437